Ozempic in Adolescents Ages 12 to 17: What You Need to Know About Off-Label Use

What Is the FDA Approval Status of Ozempic for Adolescents?

Ozempic is approved by the FDA solely for glycemic control in adults (18 and older) with type 2 diabetes, and as a cardiovascular risk reducer in adults with established cardiovascular disease. The FDA has never granted Ozempic a pediatric indication. Any prescription written for a patient ages 12 to 17 is, by definition, off-label.

This does not make it illegal. Off-label prescribing is a routine part of medicine, and physicians bear full clinical and legal responsibility for documenting why an off-label choice was made, what alternatives were considered, and that the patient and guardian received adequate informed consent.

Why the Distinction Between Ozempic and Wegovy Matters

Both Ozempic and Wegovy contain semaglutide. The difference is the dose and the approved indication. Ozempic tops out at 2.0 mg weekly for diabetes management. Wegovy delivers 2.4 mg weekly and is indicated for chronic weight management.

In December 2022, the FDA approved Wegovy specifically for adolescents aged 12 and older with an initial BMI at or above the 95th percentile for age and sex, making it the on-label semaglutide product for adolescent obesity. [1] Prescribing Ozempic instead of Wegovy in a 14-year-old with obesity therefore adds an extra layer of off-label exposure without a clinical advantage over the approved alternative.

The Regulatory Path That Created This Gap

The FDA's 2022 Wegovy approval in adolescents followed the STEP TEENS trial, which studied semaglutide 2.4 mg specifically. Because that trial used the Wegovy formulation and dosing schedule, it generated the safety and efficacy data the FDA needed for that specific product. Ozempic was never submitted for a pediatric indication, so no equivalent approval pathway was pursued for it.

What Does the Clinical Evidence Actually Show?

The strongest pediatric data come from the STEP TEENS randomized controlled trial (N=201, ages 12 to 17, BMI at or above the 95th percentile). Published in the New England Journal of Medicine in 2022, STEP TEENS found that semaglutide 2.4 mg weekly produced a mean 16.1% reduction in BMI at 68 weeks compared with a 0.6% reduction in the placebo group (P<0.001). [2] Roughly 45% of participants receiving semaglutide achieved at least a 20% reduction in BMI.

These results are clinically significant. Lifestyle intervention alone in adolescents typically produces 1 to 3% BMI reductions in controlled trial settings.

Evidence Specific to Ozempic Doses in Adolescents

Direct randomized trial data for Ozempic's specific doses (0.5 mg, 1.0 mg, 2.0 mg) in the 12 to 17 age group are essentially absent from the peer-reviewed literature. Pharmacokinetic modeling suggests semaglutide exposure at a given dose is broadly similar in adolescents and adults, but this has not been validated in a large trial using Ozempic's approved doses. [3]

A 2023 analysis in JAMA Pediatrics reviewed real-world GLP-1 receptor agonist prescribing trends in patients under 18 and found a 594% increase in GLP-1 prescriptions for adolescents between 2020 and 2023, with semaglutide accounting for the majority of that growth. [4] The same analysis noted that most prescriptions were written by endocrinologists and obesity medicine specialists rather than primary care physicians, reflecting the complexity of this decision.

Liraglutide as a Comparison Point

Before semaglutide's pediatric approval, liraglutide (Victoza, 1.2 to 1.8 mg daily) was the only GLP-1 receptor agonist with an FDA approval in patients under 18, specifically for type 2 diabetes in patients 10 and older. [5] The ELLIPSE trial (N=134, ages 10 to 17) showed liraglutide 1.8 mg reduced HbA1c by 0.64 percentage points more than placebo at 26 weeks (P<0.001). [6] Liraglutide's relative efficacy for weight loss is lower than semaglutide's, but its pediatric safety profile is better characterized.

Why Would a Clinician Prescribe Ozempic Off-Label Instead of Wegovy?

There are narrow but real clinical scenarios where a prescriber might reach for Ozempic over Wegovy in an adolescent.

Type 2 Diabetes as the Primary Indication

An adolescent with type 2 diabetes who needs glycemic control has a different primary goal than one being treated for obesity alone. In this context, a prescriber might consider the adult data for Ozempic's glycemic efficacy and weigh it against the absence of a pediatric label. The SUSTAIN-6 trial (N=3,297 adults) demonstrated that semaglutide 0.5 mg and 1.0 mg each produced HbA1c reductions of approximately 1.0 to 1.4 percentage points versus placebo. [7] However, for adolescents with T2D, the first-line GLP-1 recommendation in current guidelines is liraglutide (Victoza), which carries an actual pediatric label.

The American Diabetes Association's 2024 Standards of Care state: "Liraglutide is approved for treatment of type 2 diabetes in youth 10 years and older and should be considered when glycemic targets are not met with metformin and/or insulin." [8] No equivalent endorsement exists for Ozempic in pediatric T2D.

Access and Formulary Barriers

Wegovy has faced persistent supply shortages since 2022. Some prescribers have documented using Ozempic as a practical substitute when Wegovy is unavailable and the clinical need is urgent. The FDA formally acknowledged semaglutide supply constraints in its drug shortage database as recently as 2024. [9] This is a real-world driver of off-label use, but it does not alter the regulatory or clinical risk calculus.

Insurance Coverage Patterns

Wegovy's coverage for adolescents varies widely by payer. Several state Medicaid programs and commercial plans that cover Wegovy for adults have separate, more restrictive criteria for minors. In those cases, some prescribers have attempted to obtain Ozempic coverage under a diabetes diagnostic code. This practice carries billing compliance risks beyond the scope of clinical care.

What Are the Specific Safety Concerns in the 12 to 17 Age Group?

The safety profile of semaglutide in adolescents overlaps substantially with that in adults, but several concerns are amplified or carry unique considerations in a developing patient.

Gastrointestinal Effects and Nutritional Adequacy

Nausea, vomiting, and reduced appetite are the most common adverse effects of semaglutide across all populations. In STEP TEENS, 62% of the semaglutide group reported gastrointestinal adverse events versus 42% in the placebo group. [2] In adolescents, who may already have irregular eating patterns, persistent nausea raises specific concerns about micronutrient intake, adequate caloric intake for growth, and the potential for disordered eating behaviors to emerge or worsen.

Clinicians prescribing semaglutide in this age group should conduct a baseline eating behavior screen (such as the SCOFF questionnaire) and monitor height velocity in addition to weight. A patient who is growing in height needs sufficient energy intake even while reducing adiposity.

Bone Density and Growth

Rapid weight loss in adolescents may affect bone mineral accrual, a process that is essentially complete by the mid-20s. No long-term data exist on semaglutide's effect on bone density or final adult height in patients who begin treatment at 12 to 14. The STEP TEENS trial ran only 68 weeks, which is insufficient to assess these outcomes. [2]

Thyroid Risk

Semaglutide carries a black box warning for thyroid C-cell tumors based on rodent carcinogenicity studies. Human relevance has not been established, but the FDA requires that semaglutide be contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). [1] This contraindication applies identically to adolescents.

Psychological Considerations

Body image concerns are particularly acute in adolescence. The visible and rapid weight loss associated with semaglutide may be psychologically beneficial for some patients and destabilizing for others. A 2023 statement from the American Academy of Pediatrics emphasized that pharmacologic treatment of adolescent obesity should be integrated with behavioral support and mental health monitoring. [10]

How Should Dosing Work If a Clinician Proceeds with Off-Label Ozempic in an Adolescent?

No pediatric dosing schedule exists for Ozempic because it has no pediatric label. Clinicians who proceed off-label typically extrapolate from the adult initiation protocol.

Standard Adult Titration as the Starting Template

The standard Ozempic titration is 0.25 mg weekly for 4 weeks, then 0.5 mg weekly. The dose can be increased to 1.0 mg after at least 4 weeks at 0.5 mg if additional glycemic or weight control is needed, and to 2.0 mg after at least 4 additional weeks. [1] Given the absence of pediatric-specific pharmacokinetic data for these doses, most pediatric endocrinologists who use semaglutide off-label prefer to start at the lowest available dose and titrate slowly.

Monitoring Parameters

Minimum recommended monitoring during titration includes body weight and BMI percentile (monthly), height velocity (every 3 months), HbA1c (every 3 months), fasting lipid panel (baseline, then at 6 and 12 months), renal function (baseline and annually), and thyroid palpation at each visit. Any symptom suggesting pancreatitis (persistent severe abdominal pain radiating to the back) requires immediate discontinuation and evaluation.

What Do Current Clinical Guidelines Say?

The Endocrine Society's 2023 clinical practice guideline on pediatric obesity states that pharmacotherapy is appropriate for adolescents with BMI at or above the 95th percentile when intensive lifestyle intervention has not achieved sufficient improvement in weight-related comorbidities. [11] The guideline names semaglutide 2.4 mg (Wegovy) as the agent with the strongest evidence base in this age group.

Ozempic is not mentioned in the Endocrine Society's 2023 pediatric obesity guideline. The American Academy of Pediatrics 2023 Clinical Practice Guideline for Evaluation and Treatment of Children and Adolescents with Obesity similarly names semaglutide (at the Wegovy dose) rather than the Ozempic formulation. [10]

The American Diabetes Association 2024 Standards of Care do not include semaglutide (either formulation) in their recommended treatment algorithm for youth-onset type 2 diabetes, citing the absence of a pediatric label for the molecule's diabetes indication in this age group. Metformin and liraglutide remain the two first-line pharmacologic agents the ADA specifically endorses for pediatric T2D. [8]

Informed Consent Requirements for Off-Label Prescribing in Minors

Prescribing an off-label medication to a minor requires consent from a parent or legal guardian in addition to assent from the adolescent patient. The documentation should explicitly state that Ozempic is not FDA-approved for patients under 18, that approved alternatives (Wegovy for obesity, liraglutide for T2D) exist, why the prescriber selected Ozempic specifically, and what monitoring plan is in place.

Some state medical boards have issued specific guidance on off-label prescribing to minors. Clinicians should review their state's requirements before proceeding.

Practical Comparison: Ozempic vs. Wegovy vs. Liraglutide in Adolescents

| Feature | Ozempic (semaglutide 0.5-2.0 mg) | Wegovy (semaglutide 2.4 mg) | Victoza (liraglutide 1.2-1.8 mg) | |---|---|---|---| | FDA approval in 12-17 | None | Obesity (BMI 95th percentile+) | T2D in ages 10+ | | Injection frequency | Weekly | Weekly | Daily | | BMI reduction in teens (trial) | No direct trial data | 16.1% (STEP TEENS) | Not studied for obesity | | HbA1c reduction (adult trials) | 1.0-1.4 pp (SUSTAIN-6) | Not primary endpoint | 0.64 pp (ELLIPSE, pediatric) | | Available doses | 0.5, 1.0, 2.0 mg | 2.4 mg | 1.2, 1.8 mg | | Black box warning | Thyroid C-cell tumors | Thyroid C-cell tumors | Thyroid C-cell tumors |

When Should a Prescriber Not Use Ozempic in an Adolescent?

Absolute contraindications mirror the adult label: personal or family history of MTC, MEN2, prior serious hypersensitivity reaction to semaglutide, or personal or family history of pancreatitis. Additional relative contraindications specific to adolescents include active eating disorder (anorexia, bulimia, avoidant/restrictive food intake disorder), documented poor adherence to prior simpler regimens suggesting self-injection will not be sustained, and severe gastroparesis.

Ozempic should not be used as a substitute for Wegovy simply because it is more familiar to the prescriber or easier to obtain from a compounding pharmacy. The FDA has specifically warned that compounded semaglutide products lack bioequivalence data and should not be considered equivalent to the approved branded formulations. [9]